Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Parallel Group, Placebo and Active Controlled, Multicenter Dose Ranging Study With the Beta-3 Agonist YM178 in Patients With Symptomatic Overactive Bladder

NCT00337090 is registered in ClinicalTrials.gov with Astellas Pharma Inc as lead sponsor.

NCT NCT00337090
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00337090 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Parallel Group, Placebo and Active Controlled, Multicenter Dose Ranging Study With the Beta-3 Agonist YM178 in Patients With Symptomatic Overactive Bladder
Lead sponsor
Astellas Pharma Inc
Phase
Phase 2
Overall status
Completed
Start date
Not reported
Completion date
March 31, 2007
Enrollment
1,108 (actual)
Sites
84

Conditions

As the registry lists them; a condition with its own page is linked.

overactive bladder